index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

98

 

NOTICES

154

 

 

MOTS CLES

Arthritis Addiction Pregnancy Glucocorticoids Antibiotics Spondylitis Anxiété Management Biomarkers Pharmaco-Épidémiologie Atopic dermatitis Autoimmunity Antimicrobials Immune-related adverse events Psoriasis ArtThese Biological therapy Antibiotic misuse Dermatology Endocrine toxicity Meta-Analysis Biologic therapy Biologic Azathioprine Bacterial Biomédicaments Infliximab Cardiomyopathy Drug survival Intensive care Biological Therapy Graft-versus-host disease Antibiotic resistance Ustekinumab Anticancer drugs Psoriatic arthritis Cancer Angiotensin receptor blockers Adverse side effects Treatment Antimicrobial Stewardship Cardio-oncology Sipuleucel-T Primary adrenal insufficiency Cardiotoxicity Drug reaction Anti-HCV Direct Acting Antivirals DAA Spondyloarthritis Accelerometer Adolescent Arrhythmia Prostate cancer Amyloidosis Access to care Biologic drug Apremilast BTK protein Méta-Analyse ASDAS Beta-lactam antibiotics Ethics Immune checkpoint inhibitors Alitretinoin Placebo Quality of life Pharmacoepidemiology Etanercept COVID-19 Antimicrobial resistance Alcohol Acute Myeloid Leukaemia AML Systematic review Anxiety Biologics Sacroiliitis Albinism Burden Bacterial rhinosinusitis Autoimmune diseases Biosimilar Pharmaceuticals Angiotensin-converting enzyme inhibitors Auto-Diagnostic Atrial fibrillation Ankylosing spondylitis Anti-Bacterial Agents Axial spondyloarthritis Auto-immune hepatitis Epidemiology Abus d'antibiotiques Anti-TNF Stability Immunotherapy Apre-milast Network meta-analysis Aging Adalimumab Antimicrobiens Ankylosing Pharmacovigilance Vigibase®

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS